MGTX

MeiraGTx Holdings plc

10.03

Oct 20 • 1:29 PM ET +0.58 (6.14%)

Healthcare Biotechnology USA Small NASD

Peers: RGNX FDMT QURE ABEO IRD OCGN RCKT VYGR SLDB KRYS

| Held by: IWM FYC IBB IWO VTWO KOMP FYX JSML VHT IWC

Index	RUT
Market Cap	963.32M
Enterprise Value	932.68M
Income	78.98M
Sales	397.50M
Book/sh	2.29
Cash/sh	1.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	403
IPO	Jun 08, 2018

P/E	14.21
Forward P/E	-
PEG	-
P/S	2.42
P/B	4.38
P/C	6.73
P/FCF	92.01
EV/EBITDA	4.79
EV/Sales	2.35
Quick Ratio	3.76
Current Ratio	3.76
Debt/Eq	0.52
LT Debt/Eq	0.51
Option/Short	Yes / Yes

EPS (ttm)	0.71
EPS next Y	-1.75
EPS next Q	-0.50
EPS this Y	121.13%
EPS next Y	-683.81%
EPS next 5Y	5.92%
EPS past 3/5Y	20.90% 1.58%
Sales past 3/5Y	72.27% 39.22%
EPS Y/Y TTM	136.80%
Sales Y/Y TTM	948.35%
EPS Q/Q	455.90%
Sales Q/Q	8608.59%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	473.12% 45819.14%

Insider Own	23.34%
Insider Trans	-1.28%
Inst Own	63.22%
Inst Trans	12.96%
ROA	26.54%
ROE	72.28%
ROIC	24.26%
Gross Margin	94.90%
Oper. Margin	45.94%
Profit Margin	19.87%
SMA20	-4.62%
SMA50	-18.95%
SMA200	-1.91%
Trades

Shs Outstand	94.19M
Shs Float	73.63M
Short Float	8.14%
Short Ratio	7.67
Short Interest	6.00M
52W High	15.35 -34.66%
52W Low	6.62 51.51%
Volatility	6.00% 5.58%
ATR (14)	0.58
RSI (14)	39.42
Beta	1.08
Rel Volume	0.62
Avg Volume	781.71K
Volume	307,865

Perf Week	0.91%
Perf Month	-23.32%
Perf Quarter	-17.52%
Perf Half Y	-1.38%
Perf YTD	26.16%
Perf Year	21.72%
Perf 3Y	168.18%
Perf 5Y	-52.22%
Perf 10Y	-
Recom	1.25
Target Price	27.75
Prev Close	9.45
Price	10.03
Change %	6.14%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-26	Initiated	Goldman	Neutral	$16
Nov-24-25	Initiated	H.C. Wainwright	Buy	$20
Oct-21-25	Initiated	Raymond James	Strong Buy	$29
Jul-31-24	Resumed	Chardan Capital Markets	Buy	$36
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$27
Sep-15-20	Resumed	BofA Securities	Buy	$20
Sep-03-19	Initiated	Piper Jaffray	Overweight	$40
Feb-27-19	Reiterated	Chardan Capital Markets	Buy	$30 → $40
Jul-03-18	Initiated	BofA/Merrill	Buy
Jul-03-18	Initiated	Barclays	Overweight

Sep-23-26 08:00AM	MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors (GlobeNewswire)
Aug-26-26 10:49AM	Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical (PR Newswire)
Aug-13-26 08:00AM	MeiraGTx Reports Second Quarter 2026 Financial and Operational Results (GlobeNewswire)
Aug-06-26 04:30PM	MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-07-26 07:30AM	MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) (GlobeNewswire) +5.54%
04:30PM	Loading…
May-14-26 04:30PM	MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.53%
08:00AM	MeiraGTx Reports First Quarter 2026 Financial and Operational Results (GlobeNewswire)
May-01-26 06:18PM	Miami International, Nathan's Famous, and 3 More Stocks See Action From Activist Investors (Barrons.com)
Apr-16-26 07:47AM	MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares (GlobeNewswire) -15.73%
07:10AM	MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) (GlobeNewswire)
07:00AM	MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia (GlobeNewswire)
Apr-14-26 08:30AM	MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 (GlobeNewswire) +17.24%
Mar-26-26 08:00AM	MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results (GlobeNewswire)
Mar-09-26 08:15AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.29%
Mar-05-26 08:25AM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -5.67%
05:35PM	Loading…
Mar-03-26 05:35PM	AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-26-26 09:55AM	TG Therapeutics (TGTX) Misses Q4 Earnings Estimates (Zacks)
Feb-03-26 08:00AM	ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy (PR Newswire)
Nov-20-25 03:00PM	Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference (PR Newswire)
Nov-13-25 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Third Quarter 2025 Financial and Operational Results (GlobeNewswire)
Nov-10-25 09:15AM	Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology (GlobeNewswire)
Nov-06-25 06:25PM	Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-05-25 05:35PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
10:00AM	MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-22-25 08:18AM	MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last? (Zacks) -5.62%
Oct-07-25 08:00AM	MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress (GlobeNewswire)
Aug-14-25 09:10AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:35AM	Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Loading…
08:00AM	MeiraGTx Reports Second Quarter 2025 Financial and Operational Results (GlobeNewswire)
Aug-07-25 08:45AM	InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
May-13-25 04:30PM	MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire) -8.36% -10.00%
09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports First Quarter 2025 Financial and Operational Results (GlobeNewswire)
May-09-25 08:00AM	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease (GlobeNewswire)
Apr-10-25 09:49AM	Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? (Zacks) -5.59%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.14%
Mar-25-25 10:50AM	MeiraGTx Holdings: Gaining Regulatory Focus (SeekingAlpha)
09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-18-25 03:29AM	MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinsons Treatment (Insider Monkey)
Mar-14-25 08:27AM	MeiraGTx and Hologen launch AI-backed gene therapy venture (Pharmaceutical Technology) -5.58%
Mar-13-25 08:05AM	MeiraGTx spins Parkinsons, obesity gene therapies into AI startup (BioPharma Dive) +28.71%
08:00AM	MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
07:30AM	MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process (GlobeNewswire)
Feb-24-25 07:30AM	MeiraGTx seeks UK approval after gene therapy restores sight in children born blind (Pharmaceutical Technology)
Feb-21-25 06:30AM	MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy (GlobeNewswire) +6.88%
Jan-22-25 08:30AM	MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations (GlobeNewswire) -5.77%
Jan-20-25 03:25PM	Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-29-24 06:19AM	MeiraGTx Holdings plc (MGTX): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-10-24 09:38AM	MeiraGTx granted RMAT designation by U.S. FDA to AAV2-hAQP1 (TipRanks)
Dec-09-24 08:00AM	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire) +5.54%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-13-24 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.71%
08:00AM	MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
Oct-22-24 08:00AM	MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress (GlobeNewswire)
Oct-16-24 04:43PM	MeiraGTxs Parkinsons gene therapy shows promise in Phase I/II study (Clinical Trials Arena) +11.07%
07:30AM	MeiraGTx Holdings Reports Promising Parkinsons Therapy Results (TipRanks)
06:45AM	MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? (Zacks)
Oct-15-24 12:13PM	Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints (Benzinga) +14.87%
07:00AM	MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease (GlobeNewswire)
Oct-09-24 04:30PM	MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference (GlobeNewswire)
Aug-30-24 09:46AM	Is MeiraGTx Holdings plc (MGTX) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-12-24 07:40AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.47%
07:05AM	MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results (GlobeNewswire)
07:03AM	MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi (GlobeNewswire)
May-24-24 09:57AM	Ireland the jewel in the life sciences crown? (Medical Device Network)
May-22-24 09:32AM	Jim Cramer is Recommending These Stocks (Insider Monkey)
May-10-24 03:09PM	MeiraGTx Holdings PLC Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 01:53PM	MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00AM	MeiraGTx Reports First Quarter 2024 Financial and Operational Results (GlobeNewswire)
Apr-24-24 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-18-24 04:30PM	MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference (GlobeNewswire)
Mar-14-24 10:31AM	MeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023 (GuruFocus.com) -7.09%
09:45AM	MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:30AM	MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
Feb-13-24 08:00AM	MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals (GlobeNewswire) -9.55%
Feb-01-24 07:30AM	Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors (PR Newswire)
Jan-10-24 09:55AM	Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet (Zacks)
08:49AM	MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Jan-02-24 12:17PM	MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why (Zacks)
Dec-25-23 09:55AM	Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade (Zacks)
Dec-21-23 07:07AM	J&J bets bigger on MeiraGTxs eye gene therapy (BioPharma Dive) +32.59%
07:00AM	MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million (GlobeNewswire)
Nov-21-23 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-14-23 07:21PM	MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress (GuruFocus.com)
08:00AM	MeiraGTx Announces Third Quarter 2023 Financial and Operational Results (GlobeNewswire)
Oct-31-23 08:00AM	BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions (News Direct)
Oct-30-23 08:25AM	Sanofi invests in MeiraGTx and its gene-regulating technology (BioPharma Dive) +20.27%
07:30AM	MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities (GlobeNewswire)
Oct-24-23 08:30AM	MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress (GlobeNewswire)
Aug-10-23 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Second Quarter 2023 Financial and Operational Results (GlobeNewswire)
Aug-01-23 09:10AM	MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology (GlobeNewswire)
Jul-19-23 08:30AM	MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing (GlobeNewswire) +8.04%
Jun-28-23 07:53PM	MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks) +8.20%
Jun-27-23 03:41PM	MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness (Benzinga) -7.31%
07:30AM	MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire)
Jun-22-23 04:01PM	MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Companys Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023 (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Naylor Stuart	CHIEF SCI OFCR, OPHTHALMOLOGY	Oct 06 '26	Sale	10.64	27,659	294,292	613,187	Oct 06 08:53 PM
Naylor Stuart	Officer	Oct 06 '26	Proposed Sale	10.64	27,659	294,321		Oct 06 04:20 PM
Forbes Alexandria	PRESIDENT & CEO	Aug 18 '26	Sale	13.86	62,000	859,320	1,325,695	Aug 18 09:03 PM
Alexandria Forbes	Officer	Aug 18 '26	Proposed Sale	13.86	62,000	859,320		Aug 18 09:01 PM
Giroux Richard	CFO & COO	Jul 21 '26	Sale	12.51	56,000	700,560	908,530	Jul 21 09:12 PM
Richard Giroux	Officer	Jul 21 '26	Proposed Sale	12.51	56,000	700,560		Jul 21 09:09 PM
Naylor Stuart	CHIEF SCI OFCR, OPHTHALMOLOGY	Jul 07 '26	Sale	14.80	27,659	409,470	640,846	Jul 07 09:05 PM
Naylor Stuart	Officer	Jul 07 '26	Proposed Sale	13.33	27,659	368,694		Jul 07 09:45 AM
Forbes Alexandria	PRESIDENT & CEO	May 19 '26	Sale	9.17	62,000	568,540	1,387,695	May 19 09:05 PM
Alexandria Forbes	Officer	May 19 '26	Proposed Sale	9.17	62,000	568,540		May 19 09:03 PM
Giroux Richard	CFO & COO	Apr 21 '26	Sale	10.22	56,000	572,320	971,530	Apr 21 09:01 PM
Richard Giroux	Officer	Apr 21 '26	Proposed Sale	10.22	56,000	572,545		Apr 21 08:59 PM
Naylor Stuart	CHIEF DEV. OFFICER	Apr 07 '26	Sale	9.36	27,661	258,907	668,505	Apr 07 08:57 PM
Naylor Stuart	Officer	Apr 07 '26	Proposed Sale	9.36	27,661	258,875		Apr 07 04:17 PM
Forbes Alexandria	PRESIDENT & CEO	Mar 24 '26	Sale	7.41	62,000	459,420	1,449,695	Mar 24 09:12 PM
Alexandria Forbes	Officer	Mar 24 '26	Proposed Sale	7.41	62,000	459,420		Mar 24 09:11 PM
Giroux Richard	CFO & COO	Oct 21 '25	Sale	8.87	24,000	212,880	829,494	Oct 21 09:19 PM
Richard Giroux	Officer	Oct 21 '25	Proposed Sale	8.87	24,000	212,880		Oct 21 09:17 PM

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.

CEODr. Alexandria Forbes Ph.D.

COO & CFOMr. Richard Brian Giroux B.A.

Chief Medical OfficerDr. Robert K. Zeldin M.D.

General Counsel & SecretaryMr. Robert J. Wollin J.D.

Chief Scientific Officer of OphthalmologyDr. Stuart Naylor Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGTX

MeiraGTx Holdings plc

Upgrade your Finviz experience